Double CAR-T attack on tough leukemia: early trial opens
NCT ID NCT07201727
First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 31 times
Summary
This early-phase trial tests a two-step CAR-T cell therapy for people with relapsed or refractory acute myeloid leukemia (AML), a type of blood cancer that has not responded to standard treatments. Ten participants will receive an infusion of dual-target CAR-T cells followed by another CAR-T cell type, then a stem cell transplant. The main goal is to check safety and see if this approach can control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOID LEUKEMIA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.